Pegram M - Search Results

1

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.

Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Mahtani R, et al. Among authors: pegram m. Clin Breast Cancer. 2020 Jun;20(3):e251-e260. doi: 10.1016/j.clbc.2019.08.001. Epub 2019 Aug 21. Clin Breast Cancer. 2020. PMID: 32139271 Review.

2

HER-2/neu as a predictive marker of response to breast cancer therapy.

Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.

3

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

Pegram MD, Slamon DJ. Pegram MD, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):89-95. Semin Oncol. 1999. PMID: 10482199 Clinical Trial.

4

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.

Pegram M, Slamon D. Pegram M, et al. Semin Oncol. 2000 Oct;27(5 Suppl 9):13-9. Semin Oncol. 2000. PMID: 11049052

5

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

Slamon D, Pegram M. Slamon D, et al. Among authors: pegram m. Semin Oncol. 2001 Feb;28(1 Suppl 3):13-9. doi: 10.1016/s0093-7754(01)90188-5. Semin Oncol. 2001. PMID: 11301370 Review.

6

Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.

Pegram MD, O'Callaghan C. Pegram MD, et al. Clin Breast Cancer. 2001 Oct;2 Suppl 1:S15-9. doi: 10.3816/cbc.2001.s.003. Clin Breast Cancer. 2001. PMID: 11970740 Review.

7

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.

Pegram MD, Reese DM. Pegram MD, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37. doi: 10.1053/sonc.2002.34053. Semin Oncol. 2002. PMID: 12138395 Review.

8

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Konecny G, et al. Among authors: pegram m. J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142. J Natl Cancer Inst. 2003. PMID: 12529347

9

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Konecny GE, et al. Among authors: pegram md. Clin Cancer Res. 2004 Mar 1;10(5):1706-16. doi: 10.1158/1078-0432.ccr-0951-3. Clin Cancer Res. 2004. PMID: 15014023

10

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. Pegram MD, et al. J Natl Cancer Inst. 2004 May 19;96(10):759-69. doi: 10.1093/jnci/djh133. J Natl Cancer Inst. 2004. PMID: 15150304 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters